Bullish
Eli Lilly's stock rises after Berenberg upgrades to 'Buy' with $1,400 price target.
Eli Lilly's stock received a boost as Berenberg Bank upgraded the company to a 'Buy' rating, raising the price target to $1,400 from $1,220. This positive sentiment is further supported by the company's strong performance in the obesity and diabetes treatment sectors.
Key points
- Berenberg Bank upgrades Eli Lilly to 'Buy' with a $1,400 price target.
- Eli Lilly captures over 30% of new U.S. patients on oral weight-loss drugs.
- Eli Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026.
Sources
AI-generated from public news sources. Not financial advice.
